Two hundred-billion red blood cells are renewed in our body every single day. These erythrocytes (also known as red blood cells) are generated from bi-potent megakaryocyte-erythroid progenitor cells ...

Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin Drugs are usually approved for a specific indication on the basis of ...

Erythropoiesis-stimulating agents (ESAs) are a very effective treatment for reducing the need for transfusions in patients affected by anemia and either chronic kidney disease (CKD) or cancer. However ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

An interview with Dr. Alejandro Lazo-Langner on Management of Cancer-associated Anemia with Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update which provides ...